Macquarie Group’s Aquestive Therapeutics AQST Stock Holding History

Macquarie Group’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,707	Closed	-$16	–	1910
2024 Q1	$16	Buy	+3,707	New	+$12.3K	﹤0.01%	1702

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Macquarie Group's AQST Position: Q2 2024 in Review

Macquarie Group sold out of Aquestive Therapeutics (AQST) in Q2 2024, closing a stake of 3,707 shares — an estimated $16 sold.

Macquarie Group first reported a position in AQST in Q1 2024 and held it in 1 quarter. The position peaked at $16 in Q1 2024. 97 funds tracked by Wall St. Rank hold AQST as of Q2 2024.

Macquarie Group reported no remaining Aquestive Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 3,707 Aquestive Therapeutics shares in Q2 2024, an estimated $16.
Macquarie Group first reported a position in Aquestive Therapeutics in Q1 2024 and held it in 1 quarter.
Macquarie Group's Aquestive Therapeutics position peaked at $16 in Q1 2024.
97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.